Last updated: 11/04/2018 02:38:40
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multi-Center Study to Examine the Pharmacokinetics, Whole Body and Organ Dosimetry, and Biodistribution of Fission-Derived Iodine I 131 Tositumomab for Patients With Previously Untreated or Relapsed Follicular or Transformed Follicular Non-Hodgkin's Lymphoma
Trial description: Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints over the first 7 days following administration of the dosimetric dose. Whole body gamma camera images will be obtained on six days following the dosimetric dose. Organ and tumor dosimetry data will be generated from gamma camera counts of specific organs and tumor. All scans will be examined by an independent review panel to evaluate biodistribution of the radionuclide. Using the dosimetric data from three of the six imaging time points and the patient’s weight, a patient-specific activity (mCi) of Iodine-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). Patients will receive an infusion of unlabeled Tositumomab (450 mg) immediately followed by an infusion of the patient specific dose of tellurium-derived Iodine I 131 Tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy. Patients will be followed closely obtaining safety information during the post-treatment period, and for response and safety at 3,6,and 12 months during the first year, annually thereafter up to five years, and annually for additional safety and outcomes information up to 10 years.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Area Under the Curve (AUC) at 0 to 120, 0 to 168, and 0 to infinity hours
Timeframe: 0-120, 0-168, and 0-infinity hours from dosimetric dose (given only once on Day 0)
Maximum Concentration (Cmax) Values
Timeframe: 0 to 7 days from dosimetric dose (given only once on Day 0)
Terminal phase half-life (t½)
Timeframe: 0 to 7 days from dosimetric dose (given only once on Day 0)
Clearance (CL) Values
Timeframe: 0 to 7 days from dosimetric dose given only once on Day 0
Volume of Distribution at Steady State (Vss)
Timeframe: 0 to 7 days from dosimetric dose given only once on Day 0
Secondary outcomes:
Area Under the Curve (AUC) at 0 to 120 hours
Timeframe: 0-120 hours from dosimetric dose (given only once on Day 0)
Area Under the Curve (AUC) at 0 to 168 hours
Timeframe: 0-168 h from dosimetric dose (given only once on Day 0)
Area Under the Curve (AUC) at 0 to infinity (extrapolated)
Timeframe: 0 to infinity h from dosimetric dose (given only once on Day 0)
Maximum Concentration (Cmax) Values
Timeframe: 0 to 7 days from dosimetric dose (given only once on Day 0)
Mean residence times from Day 0 to Day 7
Timeframe: 0 to 7 days from dosimetric dose (given only once on Day 0)
Mean absorbed dose in the source organs and the target organs
Timeframe: 0 to 7 days from dosimetric dose
Number of participants with expected distribution of radioactivity in the circulatory system compared with uptake by other organs.
Timeframe: 0 to 7 days from dosimetric dose (given only once on Day 0)
Percentage of participants evaluable for confirmed response with complete response (CR), CR unconfirmed (CRu), partial response (PR), stable disease (SD), and progressive disease (PD)
Timeframe: From Baseline up to 99 Months
Duration of response
Timeframe: Week 7 to Week 260 post treatment
Progression-free survival
Timeframe: Week 7 to Week 260 post treatment
Overall Survival
Timeframe: Week 7 to Week 260 post treatment
Interventions:
Enrollment:
15
Primary completion date:
2006-04-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Lymphoma, Follicular
Product
tositumomab
Collaborators
Not applicable
Study date(s)
March 2003 to June 2013
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Inclusion criteria
- 1. At least 18 years of age
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria 1. At least 18 years of age 2. A histologically confirmed diagnosis of the following: Follicular lymphoma, Grade 1, 2, or 3 or diffuse large cell lymphoma concurrent with or following the diagnosis of follicular lymphoma (World Health Organization/Revised European-American Lymphoma [WHO/REAL] classification). International Working Formulation histological equivalents included: Follicular, small-cleaved; Follicular, mixed small-cleaved and large-cell; Follicular large-cell; or Transformed diffuse large-cell lymphoma following or concurrent with a diagnosis of follicular lymphoma. 3. Stage III or IV disease at the time of study entry (based on Ann Arbor Staging Classification) 4. Previously untreated or recurrent lymphoma after no more than 4 prior qualifying therapy regimens; steroids alone, as treatment for lymphoma, not considered a treatment regimen 5. Performance status of at least 70% on the Karnofsky Performance Scale and an anticipated survival of at least 3 months. 6. Bi dimensionally measurable disease with at least one lesion measuring greater than or equal to 2.0 cm x 2.0 cm (greater than or equal to 4.0 cm2) by computed tomography (CT) scan 7. Absolute B lymphocyte count (as determined by CD19 reactivity [flow cytometric determination of CD19+ B lymphocyte count]) of 30 to 350 cell/mm3 within 21 days prior to study enrollment 8. Absolute neutrophil count greater than or equal to 1500 cells/mm3; platelet count greater than or equal to 150,000/mm3; and hemoglobin greater than or equal to 10 g/dL within 21 days prior to study enrollment; blood products and/or growth factors not taken within 4 weeks prior to blood draw 9. Adequate renal function, defined as serum creatinine <1.5 x upper limit of normal (ULN), and hepatic function, defined as total bilirubin <1.5 x ULN and aspartate transaminase (AST) <5 x ULN, within 21 days of study enrollment 10. HAMA negative within 21 days prior to study enrollment 11. Signed IRB approved consent form prior to any study-specific procedures being implemented Exclusion criteria 1. Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 90 days of study enrollment; a unilateral bone marrow biopsy was adequate; marrow core was greater than or equal to 2.0 cm in length 2. Prior chemotherapy, biologic therapy, steroids, or radiation therapy as treatment for NHL within 28 days prior to study enrollment; subjects receiving low doses of steroids for non neoplastic disease acceptable to enter this study (“Low dose steroids” was defined as less than or equal to 10 mg of prednisone or equivalent per day.) 3. Prior rituximab therapy within 120 days prior to study enrollment 4. Prior radioimmunotherapy 5. Prior splenectomy 6. Splenomegaly defined as spleen mass greater than 700 grams, where splenic mass was defined as follows: Spleen mass = л(X x Y x Z)/6 Where X and Y are the greatest perpendicular diameters in cm on any single CT scan slice, and Z is the number of CT scan slices upon which the spleen is visible times the slice thickness in cm 7. Bulky disease as defined as any uni-dimensional measurement of lymphomatous mass exceeding 7 cm 8. Prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the subject had a generally accepted risk of recurrence less than 20% 9. Central nervous system involvement by lymphoma 10. Evidence of active infection requiring IV antibiotics at the time of study enrollment 11. Known human immunodeficiency virus (HIV) infection 12. New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation. 13. Active obstructive hydronephrosis 14. Evidence of clinically significant ascites or pleural effusion observed on screening physical examination or baseline CT scan 15. Prior myeloablative therapy 16. History of failed stem cell collection 17. Pregnant or nursing subjects (Subjects of childbearing potential had to have a negative serum pregnancy test within 21 days of study enrollment. Males and females of childbearing age had to agree to use effective contraception for up to 12 months after the radioimmunotherapy.)
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Study complete
Actual primary completion date
2006-04-12
Actual study completion date
2013-30-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereResults for study 393229/027 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website